Revance Therapeutics, Inc. (RVNC)
NASDAQ: RVNC · IEX Real-Time Price · USD
3.760
+0.120 (3.30%)
Apr 23, 2024, 10:35 AM EDT - Market open
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for RVNC stock have an average target of 14, with a low estimate of 9.00 and a high estimate of 20. The average target predicts an increase of 272.34% from the current stock price of 3.76.
Analyst Consensus: Buy
* Price targets were last updated on Mar 1, 2024.
Analyst Ratings
The average analyst rating for RVNC stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $8 → $9 | Hold | Maintains | $8 → $9 | +139.36% | Mar 1, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +219.15% | Feb 29, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $42 → $20 | Buy | Maintains | $42 → $20 | +431.91% | Feb 29, 2024 |
| Needham | Needham | Strong Buy Maintains $20 → $18 | Strong Buy | Maintains | $20 → $18 | +378.72% | Feb 29, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $12 | Strong Buy | Maintains | $15 → $12 | +219.15% | Feb 23, 2024 |
Financial Forecast
Revenue This Year
287.35M
from 234.04M
Increased by 22.78%
Revenue Next Year
390.18M
from 287.35M
Increased by 35.79%
EPS This Year
-2.35
from -3.83
EPS Next Year
-1.08
from -2.35
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 302.4M | 427.3M | 584.4M | 995.8M | 1.2B |
| Avg | 287.4M | 390.2M | 516.3M | 764.7M | 911.9M |
| Low | 267.4M | 334.2M | 421.4M | 548.6M | 649.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 29.2% | 48.7% | 49.8% | 92.9% | 57.2% |
| Avg | 22.8% | 35.8% | 32.3% | 48.1% | 19.2% |
| Low | 14.3% | 16.3% | 8.0% | 6.3% | -15.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.69 | -0.82 | 0.46 | 2.35 | 3.90 |
| Avg | -2.35 | -1.08 | 0.10 | 1.00 | 2.03 |
| Low | -3.18 | -1.20 | -0.09 | 0.15 | 0.93 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 2,149.6% | 291.0% |
| Avg | - | - | - | 852.9% | 103.4% |
| Low | - | - | - | 40.6% | -6.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.